Observational studyBMC cardiovascular disorders2025
SGLT2 inhibitors and left atrial function in heart failure with reduced or mildly reduced ejection fraction.
Observational study in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSodium-glucose cotransporter-2 (SGLT2) inhibitors reduce cardiovascular mortality and hospitalizations in heart failure (HF). However, their effects on left atrial (LA) structure and function remain unclear, particularly in patients with reduced or mildly reduced ejection fraction (EF).
methodsThis observational, cross-sectional study included 134 patients with HF and EF < 50%, divided into two groups: those receiving SGLT2 inhibitors (SGLT2+, n = 25) and those not receiving them (SGLT2-, n = 109). Echocardiographic measurements of LA volume index (LAVI), LA emptying fraction (LAEF), LA functional index (LAFI), and passive/active emptying fractions were obtained according to ASE/EACVI guidelines. Clinical, laboratory, and echocardiographic parameters were compared between groups, and correlations with LA indices were analyzed using multivariable linear regression.
resultsThe prevalence of diabetes mellitus, spironolactone use, and furosemide use was significantly higher in the SGLT2 + group (all p < 0.05). LVEF was lower (32.9 ± 6.7 vs. 38.7 ± 8.6, p = 0.002), and left ventricular volumes were larger in the SGLT2 + group, while LAFI was significantly reduced (0.12 ± 0.08 vs. 0.18 ± 0.10, p = 0.008). However, there were no significant differences in LAVI or LAEF between groups. Multivariable regression identified E/A ratio, age, and LVEF as independent determinants of LAVI; posterior wall thickness and E/A ratio for LAEF; and E/A ratio, diabetes mellitus, posterior wall thickness, and interventricular septal thickness for LAFI.
conclusionSGLT2 inhibitor use was not associated with significant improvement in LA volume or functional parameters in patients with HF and reduced or mildly reduced EF. The prognostic value of LA functions appears to be primarily influenced by diastolic dysfunction and ventricular remodeling rather than SGLT2 inhibitor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.